Aldeyra (ALDX) announced the resubmission of a new drug application to the FDA for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. Per FDA agreement, the only new clinical data included in the resubmitted NDA were from the recently completed dry eye chamber trial, which achieved the primary endpoint.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALDX:
- Aldeyra Therapeutics Holds Annual Meeting with Key Votes
- Aldeyra Therapeutics: Strong Financial Position and Positive Trial Outcomes Drive Buy Rating
- Aldeyra Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Strategic Partnerships
- Aldeyra Therapeutics: Buy Rating Backed by Promising Trial Results and Strategic Opportunities
- Buy Rating for Aldeyra Therapeutics Driven by Reproxalap’s Promising Phase 3 Results and Strategic Partnership Potential with AbbVie